Skip to main content
Alliance Equity Research
AER Insights
All insights
Biotechnology & Healthcare

Helus Pharma’s Depression Trial Succeeds as Safety and Funding Questions Move Forward

Helus Pharma’s HLP003 met the primary endpoint in its first pivotal depression trial, producing a 7.6-point advantage over placebo on a symptom scale at six weeks. Patients remained on their existing antidepressants, and the benefit persisted at the study’s 12-week assessment. The results strengthen the case for an intermittent add-on treatment, although the nature of three treatment-related serious adverse events remains undisclosed. Quarterly filings show $171.1 million in cash at September 30 and continued clinical spending ahead of a second pivotal readout expected in late 2027.

8 min read
Glass capsule on a laboratory surface against an abstract neural network.

Helus Pharma’s first pivotal study of HLP003 delivered a clear improvement in depression symptoms for patients who remained on their existing antidepressants. At six weeks, the investigational drug showed a 7.6-point advantage over placebo on a widely used clinician-rated scale, and the difference remained measurable at 12 weeks. The randomized result moves the company beyond the small early study that informed expectations before the readout.

The data also put the next questions into sharper focus. Helus reported three treatment-related serious adverse events without describing them in its topline release, and a second pivotal trial will not read out until the fourth quarter of 2027. The company’s September balance sheet provides substantial funding for continued development, but its filings anticipate further financing for the pipeline.

An add-on treatment for persistent symptoms

Helus, formerly Cybin, is a clinical-stage company developing medicines based on compounds that act on serotonin pathways. Its lead candidate, HLP003, is an oral, deuterated form of psilocin, a compound related to the active component of psilocybin. Deuteration changes selected hydrogen atoms in the molecule; Helus is studying the resulting compound as an intermittent treatment, rather than a second daily antidepressant.

The intended patients are adults whose depression remains inadequately controlled while taking an antidepressant. In APPROACH, participants continued a stable antidepressant and received two supervised 16 mg HLP003 doses or inactive placebo, three weeks apart. That design assesses the incremental effect of adding the drug to existing care. It does not establish its effect as a standalone treatment.

The company enrolled 223 participants; the topline analysis describes an intent-to-treat population of 222, comprising 112 assigned to HLP003 and 110 to placebo. Participants had moderate to severe major depressive disorder, with a score of at least 24 on the Montgomery-Åsberg Depression Rating Scale, or MADRS. Scores run from 0 to 60, with higher values indicating more severe symptoms. The trial population defines the evidence available today more narrowly than the total number of people diagnosed with depression.

A benefit maintained through 12 weeks

At the primary six-week assessment, the adjusted mean MADRS score fell 19.5 points from baseline with HLP003 and 11.9 points with placebo. The 7.6-point difference was statistically significant, with p<0.0001. The placebo group also improved substantially, making the between-group difference, rather than the full change in the treated group, the relevant measure of the drug’s added effect.

APPROACH outcomeHLP003Placebo
Mean MADRS improvement at six weeks19.5 points11.9 points
Response at six weeks56.3%28.2%
Remission at six weeks50.9%18.2%
Remission at 12 weeks40.2%15.5%

Source: Helus Pharma’s November 16 topline release. Mean changes are least-squares estimates; response is a reduction of at least 50% from baseline, and remission is a MADRS score of 10 or below.

The six-week remission gap was 32.7 percentage points. At 12 weeks, the adjusted mean improvement was 16.9 points with HLP003 and 9.9 points with placebo, a 7.0-point difference. Remission rates had declined in both groups from six weeks, yet the 24.7-point gap favored HLP003. These are group-level results, not evidence that every early responder remained in remission throughout the period.

An effect was also reported the day after the first dose. Helus reported a 5.0-point adjusted difference at that assessment, while the displayed rounded group changes were 16.1 and 11.0 points. The company’s published adjusted difference is the appropriate figure to use; the rounded group numbers do not reproduce it exactly.

The readout improves on the evidence available in AER’s November initiation report, which discussed a much smaller Phase 2 study and an uncontrolled long-term follow-up. Differences in sample size, design and assessment timing make a direct comparison of the two studies’ treatment effects unreliable.

Safety, blinding and the next trial

Helus said most adverse events were mild or moderate, transient and concentrated on dosing days. It also reported three HLP003 treatment-related serious adverse events. The release does not specify their nature, outcomes, whether they occurred in separate participants, or the corresponding serious-event experience in the placebo group. Those details are needed to assess the clinical significance of the reported events and the demands of treatment monitoring.

The trial used inactive placebo, so the perceptual effects associated with the drug could make treatment assignment apparent to some participants or staff. Helus says its study design used independent remote raters who were blinded to dose and the dosing experience, with a separation between dosing sessions and the assessment team. That safeguard addresses an important source of measurement bias, although the topline release does not report whether participants or raters correctly guessed assignments.

The second pivotal study, EMBRACE, is enrolling a planned 330 participants across 16 mg, 8 mg and placebo groups, with two administrations three weeks apart. Its primary assessment is also at six weeks. A positive result for the 16 mg regimen would provide a separate assessment of the APPROACH finding; the 8 mg arm could inform the benefit and tolerability of a lower dose. Helus expects topline results in the fourth quarter of 2027 and has targeted an FDA application in 2028.

The EXTEND study follows eligible participants from the pivotal trials and allows additional treatment after nonresponse or relapse. Its long-term observations can help clarify retreatment and safety, though participants receiving additional open-label treatment will not provide the same placebo-controlled comparison as the first 12 weeks.

The economics of supervised treatment

HLP003’s proposed role is to add periods of symptom relief while patients continue their existing antidepressants. If the effect lasts for months, two initial clinic visits followed by infrequent retreatment could be useful to patients and providers. The 12-week data support a benefit through that assessment, but they do not establish how often patients will need treatment over subsequent years.

Care delivery will affect adoption. Helus has described supervised administration and psychological support around treatment. Staff time, monitoring, transport, reimbursement for the visit and access to trained clinics can all affect the number of patients who receive treatment and the economics of providing it. The eventual label, price, monitoring requirements and payer coverage are not yet established.

An existing option illustrates the importance of the treatment setting. Spravato’s U.S. label calls for supervised dosing and at least two hours of observation; its treatment-resistant depression schedule begins twice weekly and then moves to maintenance visits. Its approved population and trial design differ from APPROACH, so these schedules do not establish comparative efficacy or the eventual HLP003 regimen. They do show why visit frequency and duration matter to capacity and patient access.

Cash, compensation and the path to EMBRACE

Helus had no revenue and reported a $103.1 million net loss for its fiscal second quarter ended September 30, 2026, versus $33.7 million a year earlier. Research expense increased to $30.3 million from $18.9 million as the clinical programs advanced. The quarter also included $65.0 million of noncash share-based compensation, up from $0.4 million; accelerated vesting and other equity awards were major contributors. Key management accounted for $60.7 million of the quarter’s share-based compensation. Operating expense excluding that charge was $39.6 million versus $28.5 million. This non-IFRS measure isolates the compensation charge; it is not cash flow and does not eliminate the potential shareholder cost of equity awards. Source: financial statements and management discussion.

The cash-flow statement shows $72.4 million used in operations in the six months through September, compared with $64.0 million a year earlier. The $150.9 million six-month loss included $76.5 million in noncash share-based compensation; a $5.9 million reduction in prepaid expenses helped offset increases in receivables and reductions in payables. Helus used a further $0.7 million in investing activities and generated $87.0 million from financing, primarily share issuance. After currency effects, cash rose to $171.1 million from $157.3 million at March 31.

The cash balance was approximately 4.8 times the latest quarter’s $35.3 million operating cash use. That simple comparison is not a runway forecast: spending, working capital and trial schedules can change. As of September 30, the company disclosed up to $84.8 million in additional study commitments over the following 24 months, contingent on materials and milestones; these are cancellable subject to possible fees and may overlap with future operating spending. Management expects further financing to develop its pipeline and meet obligations.

AER’s October Insight identified HLP003’s first pivotal readout as the nearer catalyst and examined the separate HLP004 anxiety program. The new result provides meaningful clinical evidence for the lead asset. The next major value driver is whether EMBRACE can reproduce the 16 mg benefit with a sufficiently characterized safety profile, while EXTEND clarifies how often patients need additional treatment.

This material is provided for informational and educational purposes only and does not constitute investment advice or a recommendation to buy or sell any security.

Companies Discussed

About AER Insights

Alliance Equity Research publishes timely insights on company-specific developments, industry trends, capital markets activity, and emerging investment themes across global public markets, with a particular focus on undercovered companies, sectors, and developments that often receive limited attention from mainstream financial research. Our analysis focuses on the financial, strategic, and valuation implications behind the headlines, using company disclosures, filings, market data, and sector context to help investors understand what matters, why it matters, and what to watch next.

Get AER Insights by Email

Receive new AER Insights and research updates in your inbox.

Subscribe
Unlabeled vaccine vial in a laboratory with an illustrative blood-cell background.Biotechnology & Healthcare

SELLAS Reports a Survival Benefit in AML as Its Cancer Vaccine Approaches FDA Review

SELLAS Life Sciences reported that its investigational cancer vaccine met the overall-survival endpoint in a Phase 3 trial of patients with acute myeloid leukemia who had reached a second or later remission and could not undergo a donor stem cell transplant. Median survival was 24.0 months with galinpepimut-S versus 14.7 months with investigator-selected care. The result provides a basis for a planned FDA discussion, while detailed control-arm, safety and secondary-endpoint data remain important to interpretation. SELLAS ended September with $134.7 million in cash after substantial warrant exercises.

Alliance Equity ResearchNovember 17, 20267 min read
Read article
Conceptual image of an unbranded medicine vial and blood glucose meter.Biotechnology & Healthcare

Amylyx’s Detailed Avexitide Results Bring a Rare Post-Surgery Condition Closer to Treatment

Amylyx has released detailed Phase 3 results for avexitide, an experimental daily injection for recurrent low blood sugar after gastric bypass. In 78 adults receiving dietary management, the treatment reduced the rate of specified hypoglycemic events over 16 weeks versus placebo. The company plans to seek U.S. approval by year-end and prepare for a possible 2027 launch. The study provides a clearer picture of the potential benefit, while diagnosis, insurance access, the approved patient population and sustained treatment will determine the commercial opportunity.

Alliance Equity ResearchNovember 15, 20266 min read
Read article
Conceptual aerial view of an open-pit mine with terraced earth and a winding haul road.Mining & Critical Minerals

Atalaya Adds Two Spanish Copper Projects as Its Growth Pipeline Competes for Capital

Atalaya Mining has acquired the former Tharsis and La Zarza mines in southern Spain for €125 million, adding large copper-bearing resources to a portfolio already led by its operating Riotinto complex and the proposed Touro development. The purchase follows a quarter of record EBITDA, helped by higher copper prices and increased sales. Although Atalaya paid €75 million upfront from cash, another €50 million is due within a year. The value of the expansion will depend on permitting, processing economics and how the new assets fit alongside existing investment priorities.

Alliance Equity ResearchNovember 13, 20267 min read
Read article
Offshore wind turbines in a line across the sea under a cloudy sky.Energy

RWE and KKR Share Capital Commitments as £12 Billion Wind Projects Advance

RWE and KKR have completed their partnership and secured financing for two British offshore wind farms requiring approximately £12 billion of investment. Each partner will own half of the projects, while RWE leads construction and delivery. Long-term power contracts provide greater revenue visibility, and project-level financing will help support development through expected commissioning in 2030. For investors, the transaction shares RWE’s capital commitments but leaves important details undisclosed, including the partners’ individual contributions. Construction costs, timing and electricity generation will determine how much value the projects ultimately deliver.

Alliance Equity ResearchNovember 11, 20266 min read
Read article
View all insights

About Alliance Equity Research

Alliance Equity Research publishes independent and company-sponsored equity research on undercovered, emerging, and high-potential public companies globally. Our analyst-built, model-backed research combines fundamental business analysis, financial forecasting, and valuation.

Email: info@alliancekp.com · Website: https://allianceequityresearch.com

For detailed company research, financial models, or coverage inquiries, contact our research team.

Research commentary for informational purposes. This document does not constitute personalized investment advice or a Buy, Hold, or Sell recommendation. For important disclosures, including information about research sponsorship and potential conflicts of interest, visit allianceequityresearch.com/disclosures.